Bioline Rx Ltd ADR(BLRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.82 | Insider Own | 0.56% | Shs Outstand | 5.0M | Perf Week | -8.85% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 19.75% | Insider Trans | - | Shs Float | 5.0M | Perf Month | -13.5% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.39 | Inst Own | 1.34% | Short Float | 2.95% | Perf Quarter | -24.93% |
| Income | -0.01B | P/S | 8.43 | EPS this Y | - | Inst Trans | 28.18% | Short Ratio | 7.59 | Perf Half Y | 7.24% |
| Sales | 0.00B | P/B | 0.75 | EPS next 5Y | - | ROA | -20.94% | Short Interest | 0.15M | Perf YTD | -14.44% |
| Book/sh | 3.15 | P/C | 0.9 | EPS past 3/5Y | 75.3% 66.78% | ROE | -47.48% | 52W High | -48.03% ($4.56) | Perf Year | -39.23% |
| Cash/sh | 2.63 | P/FCF | - | Sales past 3/5Y | - | ROIC | -47.39% | 52W Low | 10.23% ($2.15) | Perf 3Y | -96.63% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 55.29% | Gross Margin | 55.01% | Volatility(W/M) | 3.83% 4.85% | Perf 5Y | -97.88% |
| Dividend TTM | - | EV/Sales | 6.79 | Sales Y/Y TTM | -91.94% | Oper. Margin | -875.98% | ATR (14) | 0.15 | Perf 10Y | -99.66% |
| Dividend Ex-Date | - | Quick Ratio | 1.04 | EPS Q/Q | 31.62% | Profit Margin | -574.29% | RSI (14) | 39.84 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.2 | Sales Q/Q | -3.7% | SMA20 | -4.79% ($2.49) | Beta | 1.61 | Target Price | $22 |
| Payout | - | Debt/Eq | 0.58 | Earnings | 2026/8/31 | SMA50 | -10.69% ($2.65) | Rel Volume | 0.16 | Prev Close | $2.35 |
| Employees | 24 | LT Debt/Eq | 0.23 | EPS/Sales Surpr. | - -41.2% | SMA200 | -15.97% ($2.82) | Avg Volume(3M) | 0.02M | Price | $2.37 |
| IPO | 2011/7/25 | Option/Short | Yes/Yes | Trades | 56 | Volume | 3,133 | Change | 0.85% |
🧬 BiolineRx () is an Israel-based oncology-focused biotech company with a track record of securing FDA approval for its CXCR4 inhibitor motixafortide (brand name APHEXDA®) as a stem cell mobilizer for multiple myeloma. The company is currently in a combined clinical and commercialization stage, generating royalty revenue from global partnerships for the marketed APHEXDA while simultaneously advancing its clinical pipeline targeting pancreatic cancer (PDAC) and glioblastoma (motixafortide PDAC Phase 2b, GLIX1).
Over the past 1 year, on the lower side
48% below its 1-year high.
Traded less than usual That is 16% of its average volume.
BLRX has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +19.8% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $843. Peers typically go for $1,238.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.9%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.3%.
Tap to view numbers
It ranks #499 of 592 in the industry
Based on market cap of $12M.
CNSY#498 Cerenome Inc $12M PER - BLRX#499 Bioline Rx Ltd ADR $12M PER - 
PHIO#500 Phio Pharmaceuticals Corp $11M PER - 
KPRX#501 Kiora Pharmaceuticals Inc $11M PER - 
INTS#502 Intensity Therapeutics Inc $11M PER - 
FAQ
What kind of company is BLRX?
BLRX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BLRX?
The market cap of BLRX is approximately $12M, ranking 5,437 within its sector.
What is the 52-week high and low for BLRX?
BLRX has recorded a 52-week high of $4.56 and a low of $2.15.
